Better Health for All

Protagonist Therapeutics' core business is developing novel drug candidates for unmet medical needs, with its entire business devoted to health improvement. Its lead candidate, rusfertide, demonstrated a 77% clinical response rate in Phase 3 trials for polycythemia vera, significantly higher than placebo (33%), meeting primary and all key secondary endpoints.

Rusfertide was generally well tolerated in Phase 3 and Phase 2 REVIVE studies, with no new safety signals or evidence of increased cancer risk; most adverse events were mild injection site reactions. The company received a $300 million upfront payment and will receive additional milestone payments and royalties for rusfertide, indicating substantial investment in health innovation. Protagonist Therapeutics has an expanded access policy for investigational medicines, but the articles do not provide details on the criteria or scope of this policy. The company also states it has a compliance program with employee training on its Code of Conduct and regular policy reviews.

Fair Money & Economic Opportunity

Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on research and development of novel drug candidates.

The provided articles do not contain any specific, concrete data points related to the company's involvement in lending, insuring, moving, or storing money, or any other activities relevant to the 'Fair Money & Economic Opportunity' value, which primarily assesses financial institutions. Therefore, all Key Performance Indicators for this value must be omitted due to a lack of direct evidence in the provided articles.

Fair Pay & Worker Respect

For fiscal year 2024, Protagonist Therapeutics reported a CEO-to-median employee pay ratio of 35:1.

The company covers 100% of employee monthly healthcare premiums, including for spouses and dependents. No regulatory actions, violations, fines, or compliance issues related to labor were mentioned in the provided articles.

Fair Trade & Ethical Sourcing

The company's Code of Business Conduct and Ethics, last amended on March 31, 2022,

outlines general ethical conduct, legal compliance, and internal controls, including adherence to the Foreign Corrupt Practices Act. However, the provided articles do not contain specific quantitative data or explicit statements regarding the percentage of supplier contracts that include enforceable ethical-sourcing clauses. There is no evidence of fair-trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability coverage, remediation speed for violations, or the share of procurement budget directed to diverse suppliers. The company's primary focus on research and development, with outsourced manufacturing, suggests an indirect supply chain, but no specific data on ethical sourcing practices within this chain is available.

Honest & Fair Business

The company has a whistleblower policy with a 24/7 anonymous hotline and web form, an explicit non-retaliation policy, and the Audit Committee is promptly notified of complaints, determines action, and maintains a log tracking receipt, investigation, and resolution.

Protagonist Therapeutics has had zero financial restatements in the past five years. The board has five independent directors out of six, resulting in approximately 83% independent directors. The company has a comprehensive anti-corruption policy that applies to all officers, directors, and employees, explicitly complies with the Foreign Corrupt Practices Act (FCPA), and prohibits payments to government officials to obtain business. The Audit Committee oversees the company's corporate accounting and financial reporting processes and audits of its financial statements, and reviews annual and quarterly financial statements with management and the independent auditor.

Kind to Animals

Protagonist Therapeutics, as a biopharmaceutical company, relies on animal testing for its drug development, including its pipeline products, due to regulatory requirements.

There is no public information available regarding the company's investment in or use of alternative testing methods, nor are there public animal welfare policies or initiatives.

Planet-Friendly Business

No specific, quantifiable data points or certifications were found in the provided articles that directly map to the quantitative thresholds of the 'Planet-Friendly Business' KPIs. While the company states a policy to conduct business in an environmentally responsible way, minimize environmental impacts, reduce waste, and comply with environmental laws, these are general commitments rather than measurable outcomes.

Initiatives such as supporting electric vehicle charging at headquarters, providing public transportation benefits, offering flexible working arrangements, and encouraging limited business travel are noted as efforts to reduce the company's carbon footprint, but they do not provide the specific metrics required by the rubric's KPIs.

Zero Waste & Sustainable Products

No specific, quantitative data points related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education were found in the provided articles for PTGX.US.

Several articles explicitly state the absence of such information, or focus on general ESG statements, financial reporting, or unrelated environmental efforts like electric vehicle support and public transportation access.